VINC — Vincerx Pharma Share Price
0.000.00%
Last trade - 00:00- $0.27m
- -$4.16m
- 15
- 57
- 12
- 17
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.14 | ||
| Price to Tang. Book | 0.14 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -1406.44% | ||
| Return on Equity | -3136.43% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | n/a | n/a | n/a | 0.22 | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Vincerx Pharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing differentiated and novel therapies to address the unmet medical needs of patients with cancer. It has a next generation bioconjugation platform, called VersAptx. Its product candidates include VIP943 (CD123-KSPi), VIP924 (CXCR5-KSPi), VIP236, and Enitociclib (positive transcription elongation factor beta (P-TEFb)/CDK9 inhibitor). Its VIP943 is developed using its VersAptx platform and combines an anti-CD123 antibody, a novel legumain-cleavable linker and a kinesin spindle protein inhibitor payload enhanced with CellTrapper technology. Enitociclib is a selective CDK9 inhibitor. Enitociclib effectively blocks P-TEFb-mediated activation of RNA polymerase II, preventing transcription of MCL1 and MYC, proteins associated with poor prognosis in various types of cancer.
Directors
- Ahmed Hamdy CHM (56)
- Raquel Izumi PRE (51)
- Alexander Seelenberger F. CFO (42)
- Tom Thomas GCN (56)
- Hermes Garbaen OTH (53)
- Andrew McDonald DRC (47)
- Laura Bushnell IND (53)
- Brian Druker IND (65)
- John Lee IND (53)
- Christopher Lowe IND (53)
- Mark McCamish IND (69)
- Francisco Salva IND (51)
- Ruth Stevens IND (62)
- Last Annual
- December 31st, 2024
- Last Interim
- March 31st, 2025
- Incorporated
- December 19th, 2018
- Public Since
- March 10th, 2020
- No. of Shareholders
- 8
- No. of Employees
- 12
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- Pink Sheets on Nasdaq
- Shares in Issue
- 5,234,277
- Address
- 260 Sheridan Avenue, Suite 400, PALO ALTO, 94306
- Web
- https://vincerx.com/
- Phone
- +1 6508006676
- Auditors
- WithumSmith Brown PC
Upcoming Events for VINC
Q2 2025 Vincerx Pharma Inc Earnings Release
Q3 2025 Vincerx Pharma Inc Earnings Release
Similar to VINC
Actavia Life Sciences
Pink Sheets on Nasdaq
Acura Pharmaceuticals
Pink Sheets on Nasdaq
Adhera Therapeutics
Pink Sheets on Nasdaq
Ramoil Management
Pink Sheets on Nasdaq
Adynxx
Pink Sheets on Nasdaq
FAQ
What is the Vincerx Pharma share price?
As of Today at 20:43 UTC, shares in Vincerx Pharma are trading at $0.06. This share price information is delayed by 15 minutes.
How has the Vincerx Pharma share price performed this year?
Shares in Vincerx Pharma last closed at $0.06 and the price had moved by -99.54% over the past 365 days. In terms of relative price strength the Vincerx Pharma share price has underperformed the S&P500 Index by -99.58% over the past year.
What are the analyst and broker recommendations for Vincerx Pharma?
The overall consensus recommendation for Vincerx Pharma is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Vincerx Pharma dividend yield?
Vincerx Pharma does not currently pay a dividend.
Does Vincerx Pharma pay a dividend?
Vincerx Pharma does not currently pay a dividend.
When does Vincerx Pharma next pay dividends?
Vincerx Pharma does not currently pay a dividend.
How do I buy Vincerx Pharma shares?
To buy shares in Vincerx Pharma you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Vincerx Pharma?
As of the previous close price of $0.06, shares in Vincerx Pharma had a market capitalisation of $0.29m.
Where are Vincerx Pharma shares listed?
Here are the trading details for Vincerx Pharma:
- Country of listing: United States
- Exchange: PNK
- Ticker Symbol: VINC
What kind of share is Vincerx Pharma?
Based on an overall assessment of its quality, value and momentum Vincerx Pharma is currently classified as a Value Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Vincerx Pharma share price forecast for 2025?
The analyst consensus target price for shares in Vincerx Pharma is $200.00. That is 363536.36% above the last closing price of $0.06.
Analysts covering Vincerx Pharma currently have a consensus Earnings Per Share (EPS) forecast of -$12.00 for the next financial year.
Find out moreWhat is the trend in the Vincerx Pharma share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Vincerx Pharma. Over the past six months, its share price has underperformed the S&P500 Index by -98.57%.
As of the last closing price of $0.06, shares in Vincerx Pharma were trading -98.65% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Vincerx Pharma PE Ratio?
The Vincerx Pharma PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.06.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Vincerx Pharma?
Vincerx Pharma's management team is headed by:
- Ahmed Hamdy - CHM
- Raquel Izumi - PRE
- Alexander Seelenberger F. - CFO
- Tom Thomas - GCN
- Hermes Garbaen - OTH
- Andrew McDonald - DRC
- Laura Bushnell - IND
- Brian Druker - IND
- John Lee - IND
- Christopher Lowe - IND
- Mark McCamish - IND
- Francisco Salva - IND
- Ruth Stevens - IND